<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37810405</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2090-0007</ISSN><JournalIssue CitedMedium="Print"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of transplantation</Title><ISOAbbreviation>J Transplant</ISOAbbreviation></Journal><ArticleTitle>Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group.</ArticleTitle><Pagination><StartPage>8865364</StartPage><MedlinePgn>8865364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8865364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/8865364</ELocationID><Abstract><AbstractText>Pakistan is the fifth most populous country with a population of 225 million and has health expenditure accounting for only 2.8 percent of gross domestic product (GDP). Accordingly, there are a limited number of haematology-oncology and transplant centers in the country. The Pakistan Blood and Marrow Transplant (PBMT) group was established in 2020, and this report is the first activity survey from January 2021 to December 2022 focusing on the trends of matched-related donor, haploidentical, and autologous transplants in a developing country. A total of 12 transplant centers contributed data on the modified PBMT survey form retrospectively and 806 haematopoietic stem cell transplants (HSCTs) were carried out during the study duration. Allogeneic HSCT constituted 595 (73.8%) of all the transplants; this is in stark contrast to Western data, where autologous HSCT accounts for the majority of transplants. <i>&#xdf;</i>-thalassemia major and aplastic anemia were the commonest indications for allogeneic HSCT, in contrast to Western data, where acute leukemia is the leading transplant indication. Autologous transplants were more frequently performed for Hodgkin's lymphoma as compared to non-Hodgkin's lymphoma and multiple myeloma. The use of peripheral and bone marrow stem cells was comparable. A myeloablative conditioning regimen was routinely used in patients with acute leukemia. This report provides an insight of HSCT trends in Pakistan which are different from those of Western centers contributing to transplant data from South Asia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Natasha Ali et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4990-330X</Identifier><AffiliationInfo><Affiliation>Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iftikhar</LastName><ForeName>Raheel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayaz Mir</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3287-9016</Identifier><AffiliationInfo><Affiliation>Shifa International Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bokhari</LastName><ForeName>Syed Waqas</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehman</LastName><ForeName>Jehanzeb Ur</ForeName><Initials>JU</Initials><Identifier Source="ORCID">0009-0005-5703-4556</Identifier><AffiliationInfo><Affiliation>Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaidi</LastName><ForeName>Uzma</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1593-196X</Identifier><AffiliationInfo><Affiliation>National Institute of Blood Diseases, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasir</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Quaid-e-Azam International Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adil</LastName><ForeName>Salman Naseem</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satti</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shifa International Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nisa Chaudhry</LastName><ForeName>Qamar Un</ForeName><Initials>QU</Initials><AffiliationInfo><Affiliation>Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gambat Institute of Medical Sciences, Gambat, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farzana</LastName><ForeName>Tasneem</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Children's Hospital Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghafoor</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahsan</LastName><ForeName>Bushra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Azhar S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Shifa International Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Farrukh Ali</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fatima</LastName><ForeName>Syeda Itrat</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Pakistan Institute of Medical Sciences, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samad</LastName><ForeName>Shafaq Abdul</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>National Institute of Blood Diseases, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batool</LastName><ForeName>Aliya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Akbar Niazi Teaching Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadeem</LastName><ForeName>Hafiz Muhammad</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Gambat Institute of Medical Sciences, Gambat, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbas Bukhari</LastName><ForeName>Syed Nasir</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>The Children's Hospital Lahore, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Saqib Hussain</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0002-4209-6560</Identifier><AffiliationInfo><Affiliation>Children's Hospital Karachi, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Parvez</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Quaid-e-Azam International Hospital, Islamabad, Pakistan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gambat Institute of Medical Sciences, Gambat, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Transplant</MedlineTA><NlmUniqueID>101519118</NlmUniqueID><ISSNLinking>2090-0007</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37810405</ArticleId><ArticleId IdType="pmc">PMC10555501</ArticleId><ArticleId IdType="doi">10.1155/2023/8865364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Henig I., Zuckerman T. Hematopoietic stem cell transplantation-50 years of evolution and future perspectives. Rambam Maimonides Med J . 2014;5(4) doi: 10.5041/rmmj.10162.</Citation><ArticleIdList><ArticleId IdType="doi">10.5041/rmmj.10162</ArticleId><ArticleId IdType="pmc">PMC4222417</ArticleId><ArticleId IdType="pubmed">25386344</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamsi T., Hashmi K., Adil S., et al. The stem cell transplant program in Pakistan--the first decade. Bone Marrow Transplantation . 2008;42(S1):S114&#x2013;S117. doi: 10.1038/bmt.2008.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2008.137</ArticleId><ArticleId IdType="pubmed">18724282</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldometers. Pakistan population. 2023.  
 https://www.worldometers.info/world-population/pakistan-population/
</Citation></Reference><Reference><Citation>World bank. Current health expenditure (% of GDP)-pakistan. 2023.  
 https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS
.</Citation></Reference><Reference><Citation>Passweg J. R., Baldomero H., Basak G. W., et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation . 2019;54(10):1575&#x2013;1585. doi: 10.1038/s41409-019-0465-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-019-0465-9</ArticleId><ArticleId IdType="pmc">PMC6957459</ArticleId><ArticleId IdType="pubmed">30728439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehsan H., Wahab A., Anwer F., Iftikhar R., Yousaf M. N. Prevalence of transfusion transmissible infections in beta-thalassemia major patients in Pakistan: a systematic review. Cureus . 2020;12(8) doi: 10.7759/cureus.10070.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.10070</ArticleId><ArticleId IdType="pmc">PMC7455379</ArticleId><ArticleId IdType="pubmed">32874814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali N., Moiz B., Bin Azhar W., Zaidi N., Memon R. Carrier detection for beta-thalassemia trait in general Pakistani population: a way forward. Hematology . 2012;17(4):237&#x2013;240. doi: 10.1179/1607845412y.0000000002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1607845412y.0000000002</ArticleId><ArticleId IdType="pubmed">22889518</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S., Jafri H., Rashid Y., Ehsan Y., Bashir S., Ahmed M. Cascade screening for beta-thalassemia in Pakistan: development, feasibility and acceptability of a decision support intervention for relatives. European Journal of Human Genetics . 2022;30(1):73&#x2013;80. doi: 10.1038/s41431-021-00918-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-021-00918-6</ArticleId><ArticleId IdType="pmc">PMC8200315</ArticleId><ArticleId IdType="pubmed">34121090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah K., Khan B., Raza S., et al. Bone marrow transplant cure for beta-thalassaemia major: initial experience from a developing country. Annals of Hematology . 2008;87(8):655&#x2013;661. doi: 10.1007/s00277-008-0478-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-008-0478-8</ArticleId><ArticleId IdType="pubmed">18458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed P., Chaudhry Q. U. N., Satti T. M., et al. Epidemiology of aplastic anemia: a study of 1324 cases. Hematology . 2020;25(1):48&#x2013;54. doi: 10.1080/16078454.2019.1711344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16078454.2019.1711344</ArticleId><ArticleId IdType="pubmed">31906834</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry Q. U. N., Iftikhar R., Satti T. M., et al. Outcome of fludarabine-based conditioning in high-risk aplastic anemia patients undergoing matched related donor transplantation: a single-center study from Pakistan. Biology of Blood and Marrow Transplantation . 2019;25(12):2375&#x2013;2382. doi: 10.1016/j.bbmt.2019.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2019.07.029</ArticleId><ArticleId IdType="pubmed">31394274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi U., Fatima M., Samad S. A., et al. Fludarabine/cyclophosphamide conditioning regimen in aplastic anemia patients receiving matched-sibling donor transplant is non-inferior to ATG/cyclophosphamide: a single-center experience from Pakistan. Stem Cells International . 2022;2022:11. doi: 10.1155/2022/1442613.1442613</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/1442613</ArticleId><ArticleId IdType="pmc">PMC9481407</ArticleId><ArticleId IdType="pubmed">36117722</ArticleId></ArticleIdList></Reference><Reference><Citation>Taj M., Shah T., Aslam S. K., et al. Environmental determinants of aplastic anemia in Pakistan: a case-control study. Journal of Public Health . 2016;24(5):453&#x2013;460. doi: 10.1007/s10389-016-0743-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10389-016-0743-6</ArticleId><ArticleId IdType="pmc">PMC5025505</ArticleId><ArticleId IdType="pubmed">27695669</ArticleId></ArticleIdList></Reference><Reference><Citation>Wali R., Fadoo Z., Adil S., Naqvi M. A. Aplastic anemia: clinicohaematological features, treatment and outcome analysis. Journal of the College of Physicians and Surgeons Pakistan . 2011;21(4):219&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">21453618</ArticleId></ArticleIdList></Reference><Reference><Citation>de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood . 2007;109(4):1408&#x2013;1413. doi: 10.1182/blood-2006-03-011908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-03-011908</ArticleId><ArticleId IdType="pubmed">17062730</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstone A. H., Richards S. M., Lazarus H. M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Blood . 2008;111(4):1827&#x2013;1833. doi: 10.1182/blood-2007-10-116582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-10-116582</ArticleId><ArticleId IdType="pubmed">18048644</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreth J., Schlenk R., Kopecky K. J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA . 2009;301(22):2349&#x2013;2361. doi: 10.1001/jama.2009.813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.813</ArticleId><ArticleId IdType="pmc">PMC3163846</ArticleId><ArticleId IdType="pubmed">19509382</ArticleId></ArticleIdList></Reference><Reference><Citation>Juliusson G., Karlsson K., Lazarevic V., et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. Cancer . 2011;117(18):4238&#x2013;4246. doi: 10.1002/cncr.26033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.26033</ArticleId><ArticleId IdType="pubmed">21387283</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians . 2016;66(1):7&#x2013;30. doi: 10.3322/caac.21332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21332</ArticleId><ArticleId IdType="pubmed">26742998</ArticleId></ArticleIdList></Reference><Reference><Citation>Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine . 2002;346(4):235&#x2013;242. doi: 10.1056/nejmoa011795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa011795</ArticleId><ArticleId IdType="pubmed">11807147</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah G. L., Moskowitz C. H. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood . 2018;131(15):1689&#x2013;1697. doi: 10.1182/blood-2017-09-772673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2017-09-772673</ArticleId><ArticleId IdType="pmc">PMC5897866</ArticleId><ArticleId IdType="pubmed">29500170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehn L. H., Herrera A. F., Flowers C. R., et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Journal of Clinical Oncology . 2020;38(2):155&#x2013;165. doi: 10.1200/jco.19.00172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.19.00172</ArticleId><ArticleId IdType="pmc">PMC7032881</ArticleId><ArticleId IdType="pubmed">31693429</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar S. V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. American Journal of Hematology . 2020;95(5):548&#x2013;567. doi: 10.1002/ajh.25791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25791</ArticleId><ArticleId IdType="pubmed">32212178</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel U., Usmani S., Kumar S. Current approaches to management of newly diagnosed multiple myeloma. American Journal of Hematology . 2022;97(Suppl 1):S3&#x2013;S25. doi: 10.1002/ajh.26512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26512</ArticleId><ArticleId IdType="pubmed">35234302</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlogie B., Kyle R. A., Anderson K. C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology . 2006;24(6):929&#x2013;936. doi: 10.1200/jco.2005.04.5807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2005.04.5807</ArticleId><ArticleId IdType="pubmed">16432076</ArticleId></ArticleIdList></Reference><Reference><Citation>Koreth J., Cutler C. S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biology of Blood and Marrow Transplantation . 2007;13(2):183&#x2013;196. doi: 10.1016/j.bbmt.2006.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2006.09.010</ArticleId><ArticleId IdType="pubmed">17241924</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratwohl A., Baldomero H., Gratwohl M., et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica . 2013;98(8):1282&#x2013;1290. doi: 10.3324/haematol.2012.076349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2012.076349</ArticleId><ArticleId IdType="pmc">PMC3729910</ArticleId><ArticleId IdType="pubmed">23508009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R., Kimura F., Ahn K. W., et al. Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions. Biology of Blood and Marrow Transplantation . 2016;22(5):932&#x2013;940. doi: 10.1016/j.bbmt.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2016.01.012</ArticleId><ArticleId IdType="pmc">PMC4826285</ArticleId><ArticleId IdType="pubmed">26797402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacigalupo A., Sormani M. P., Lamparelli T., et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica . 2004;89(10):1238&#x2013;1247.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477210</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>